News and Press Releases

Samsung Biologics completes acquisition of GSK’s manufacturing facility in Rockville, Maryland

Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support Plans...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: March 31, 2026

300, Songdo bio-daero, Yeonsu-gu, Incheon, Republic of Korea

University of Colorado Grants License to Cirena for RNA-Synthesis Technology

Foundational synthesis technology enables scalable modified 100-400nt RNA constructs, speeding design cycles and improving genome-editing precision 10 March 2026 -- Colorado, US -- Cirena has secured a license to the...

Category: Biotechnology, Drug Discovery, Manufacturing and Packing, Other
Posted: March 10, 2026

3415 Colorado Avenue Boulder, CO 80303

Immuthera Announces Global Exclusive License from City of Hope for First-in-Class CD6/CTLA-4 CAR-Treg Platform for Autoimmune and Inflammatory Diseases

Global exclusivity for Type 1 Diabetes, Rheumatoid Arthritis, 8 Dermatological Autoimmune diseases, and 13 Neuroinflammatory Autoimmune diseases Six patients with Chronic Graft versus Host Disease treated to-date with a favorable...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026

Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer

Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...

Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025

980 Great West Rd, London TW8 9GS

Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA

6 October 2025 -- London, UK -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical leader, have signed exclusive licensing agreements...

Category: Logistics, Other, Pharmaceutical
Posted: October 6, 2025

1 New Burlington Place, London, W1S 2HR

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma 

Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7 Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed UK...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2025

980 Great West Rd, London TW8 9GS

Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis 10 December 2024 -- London, UK -- Relation, an industry leader in deploying computation and...

Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024

Regent’s Place 338 Euston Road London NW1 3BG

ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement

Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications 04 September 2024 – Dublin, Ireland, and Cheshire, UK – ERS...

Category: BioManufacturing
Posted: September 9, 2024

8th Floor, Block E, Iveagh Court, Harcourt Road, Dublin D02 YT22, Ireland

Touchlight to Supply GMP dbDNA to Support University of Nottingham’s Clinical Study for a Next-Generation Vaccine for Zika Virus

21 August 2024 -- Hampton, UK -- Touchlight, an innovation-driven contract development and manufacturing organization (CDMO) specializing in enzymatic DNA production, is proud to announce the clinical supply of its proprietary...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 21, 2024

Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing

Agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing 23 July 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO...

Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: July 23, 2024

Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

Touchlight and LenioBio Collaborate to Accelerate Development of Protein Therapeutics for Pandemic Response

Touchlight to participate in LenioBio’s recently announced grant from CEPI 2 July 2024 -- Hampton, UK, and Düsseldorf, Germany -- LenioBio, a biotech company pioneering cell-free protein production, and Touchlight,...

Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: July 2, 2024

Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

GSK’s Omjjara▼ (momelotinib) is accepted for use within NHS Scotland, in line with its licence, for eligible adult myelofibrosis patients with moderate to severe anaemia

Clinicians in Scotland will now have the option to use momelotinib for the treatment of disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia Momelotinib is...

Category: Other, Pharmaceutical
Posted: June 10, 2024

980 Great West Rd, London TW8 9GS

GSK’s Jemperli▼ (dostarlimab) is accepted for use within NHS Scotland, in line with its licence, in eligible endometrial cancer patients in first line setting

Clinicians in Scotland will now be able to use dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced...

Category: Pharmaceutical
Posted: April 8, 2024

University of Liverpool to Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical Study

The UK’s Medical Research Council is funding a 10-patient phase 1 study to deliver rapid personalised treatment for lung cancer patients 3 April 2024 -- Hampton, UK -- Touchlight, a...

Category: Biotechnology, Clinical Trials
Posted: April 3, 2024

Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

Touchlight Awarded Tender to Supply Enzymatic dbDNA to CPI’s RNA Centre of Excellence

28 March 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO enabling the development of genetic medicines with its doggybone DNA (dbDNA) technology and leaders in enzymatic DNA production, is...

Category: Biotechnology
Posted: March 28, 2024

Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER